Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Rituximab in Membranous Nephropathy

Gauckler, Philipp ; Shin, Jae Il ; Alberici, Federico ; Audard, Vincent ; Bruchfeld, Annette ; Busch, Martin ; Cheung, Chee Kay ; Crnogorac, Matija ; Delbarba, Elisa and Eller, Kathrin , et al. (2021) In Kidney International Reports 6(4). p.881-893
Abstract

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function.... (More)

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
B cells, membranous nephropathy, nephrotic syndrome, rituximab
in
Kidney International Reports
volume
6
issue
4
pages
881 - 893
publisher
Elsevier
external identifiers
  • scopus:85102860879
  • pmid:33912740
ISSN
2468-0249
DOI
10.1016/j.ekir.2020.12.035
language
English
LU publication?
yes
id
c35f8260-ec65-41ee-91e9-0c3af1c1ab4d
date added to LUP
2021-04-06 12:38:36
date last changed
2024-06-15 09:14:19
@article{c35f8260-ec65-41ee-91e9-0c3af1c1ab4d,
  abstract     = {{<p>Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”</p>}},
  author       = {{Gauckler, Philipp and Shin, Jae Il and Alberici, Federico and Audard, Vincent and Bruchfeld, Annette and Busch, Martin and Cheung, Chee Kay and Crnogorac, Matija and Delbarba, Elisa and Eller, Kathrin and Faguer, Stanislas and Galesic, Kresimir and Griffin, Siân and van den Hoogen, Martijn W.F. and Hrušková, Zdenka and Jeyabalan, Anushya and Karras, Alexandre and King, Catherine and Kohli, Harbir Singh and Mayer, Gert and Maas, Rutger and Muto, Masahiro and Moiseev, Sergey and Odler, Balazs and Pepper, Ruth J. and Quintana, Luis F. and Radhakrishnan, Jai and Ramachandran, Raja and Salama, Alan D. and Schönermarck, Ulf and Segelmark, Mårten and Smith, Lee and Tesař, Vladimír and Wetzels, Jack and Willcocks, Lisa and Windpessl, Martin and Zand, Ladan and Zonozi, Reza and Kronbichler, Andreas}},
  issn         = {{2468-0249}},
  keywords     = {{B cells; membranous nephropathy; nephrotic syndrome; rituximab}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{881--893}},
  publisher    = {{Elsevier}},
  series       = {{Kidney International Reports}},
  title        = {{Rituximab in Membranous Nephropathy}},
  url          = {{http://dx.doi.org/10.1016/j.ekir.2020.12.035}},
  doi          = {{10.1016/j.ekir.2020.12.035}},
  volume       = {{6}},
  year         = {{2021}},
}